Genentech, Inc and OSI Pharmaceuticals, Inc announced that a randomized phase-III study (BeTa Lung) evaluating Avastin (bevacizumab) in combination with Tarceva (erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo.
The details can be read here.
No comments:
Post a Comment